国际肿瘤学杂志››2020,Vol. 47››Issue (6): 377-380.doi:10.3760/cma.j.cn371439-20191216-00040
收稿日期:
2019-12-16修回日期:
2020-01-09出版日期:
2020-06-08发布日期:
2020-07-22通讯作者:
陶凯雄 E-mail:kaixiongtao@hust.edu.cn基金资助:
Zhang Ruizhi, Chen Xin, Zhang Peng, Tao Kaixiong()
Received:
2019-12-16Revised:
2020-01-09Online:
2020-06-08Published:
2020-07-22Contact:
Tao Kaixiong E-mail:kaixiongtao@hust.edu.cnSupported by:
摘要:
直肠肛管黑色素瘤(ARMM)是一类起源于直肠肛管区域黏膜上皮的罕见恶性肿瘤,临床表现不典型,误诊漏诊率高。根治性手术是ARMM治疗的核心手段,尽管随着对疾病了解的深入,包括靶向治疗、免疫治疗在内的多种治疗手段得以应用于ARMM,但缺少精准的临床分级分期标准指导,ARMM的整体预后依旧较差。
张睿智, 陈鑫, 张鹏, 陶凯雄. 直肠肛管黑色素瘤的诊治新进展[J]. 国际肿瘤学杂志, 2020, 47(6): 377-380.
Zhang Ruizhi, Chen Xin, Zhang Peng, Tao Kaixiong. New progress on diagnosis and treatment of anorectal malignant melanoma[J]. Journal of International Oncology, 2020, 47(6): 377-380.
[1] | Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma[J]. Lancet, 2018,392(10151):971-984. DOI: 10.1016/S0140-6736(18)31559-9. doi:10.1016/S0140-6736(18)31559-9pmid:30238891 |
[2] | Fields AC, Goldberg J, Senturk J, et al. Contemporary surgical management and outcomes for anal melanoma: a national cancer database analysis[J]. Ann Surg Oncol, 2018,25(13):3883-3888. DOI: 10.1245/s10434-018-6769-y. doi:10.1245/s10434-018-6769-ypmid:30209727 |
[3] | Naqvi J, Lee A, Lederman A, et al. Patterns of care and survival outcomes in the treatment of anal melanoma[J]. J Gastrointest Cancer, 2020,51(1):211-216. DOI: 10.1007/s12029-019-00238-5. doi:10.1007/s12029-019-00238-5pmid:30982929 |
[4] | Ren M, Lu Y, Lv J, et al. Prognostic factors in primary anorectal melanoma: a clinicopathological study of 60 cases in China[J]. Hum Pathol, 2018,79:77-85. DOI: 10.1016/j.humpath.2018.05.004. doi:10.1016/j.humpath.2018.05.004pmid:29763716 |
[5] | Nam S, Kim CW, Baek SJ, et al. The clinical features and optimal treatment of anorectal malignant melanoma[J]. Ann Surg Treat Res, 2014,87(3):113-117. DOI: 10.4174/astr.2014.87.3.113. doi:10.4174/astr.2014.87.3.113 |
[6] | Manabe S, Boku Y, Takeda M, et al. Endoscopic submucosal dissection as excisional biopsy for anorectal malignant melanoma: a case report[J]. World J Clinl Cases, 2019,7(13):1652-1659. DOI: 10.12998/wjcc.v7.i13.1652. |
[7] | Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, et al. Extracutaneous melanomas: a primer for the radiologist[J]. Insights Imaging, 2015,6(6):707-717. DOI: 10.1007/s13244-015-0427-8. doi:10.1007/s13244-015-0427-8pmid:26334521 |
[8] | Park HJ, Kim HJ, Park SH, et al. JOURNAL CLUB: primary anorectal melanoma: MRI findings and clinicopathologic correlations[J]. AJR Am J Roentgenol, 2018,211(2):W98-W108. DOI: 10.2214/AJR.17.18807. doi:10.2214/AJR.17.18807pmid:29927334 |
[9] | Wang S, Sun S, Liu X, et al. Endoscopic diagnosis of primary anorectal melanoma[J]. Oncotarget, 2017,8(30):50133-50140. DOI: 10.18632/oncotarget.15495. doi:10.18632/oncotarget.15495pmid:28412758 |
[10] | Zou S, Cheng Z, Song S, et al. Anal malignant melanoma manifesting hepatic metastases shown on FDG PET/CT[J]. Clin Nucl Med, 2018,43(5):386-388. DOI: 10.1097/RLU.000000000000-2056. doi:10.1097/RLU.0000000000002056pmid:29517546 |
[11] | Falch C, Mueller S, Kirschniak A, et al. Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with18F-FDG-PET/CT[J]. World J Surg Oncol, 2016,14(1):185. DOI: 10.1186/s12957-016-0938-x. doi:10.1186/s12957-016-0938-xpmid:27422527 |
[12] | Valpione S, Gremel G, Mundra P, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients[J]. Eur J Cancer, 2018,88:1-9. DOI: 10.1016/j.ejca.2017.10.029. doi:10.1016/j.ejca.2017.10.029pmid:29175734 |
[13] | Chen H, Cai Y, Liu Y, et al. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis[J]. Medicine (Baltimore), 2016,95(7):e2770. DOI: 10.1097/MD.0000000000002770. doi:10.1097/MD.0000000000002770 |
[14] | Ford MM, Kauffmann RM, Geiger TM, et al. Resection for anal melanoma: is there an optimal approach?[J]. Surgery, 2018,164(3):466-472. DOI: 10.1016/j.surg.2018.05.026. doi:10.1016/j.surg.2018.05.026pmid:30041967 |
[15] | Matsuda A, Miyashita M, Matsumoto S, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review[J]. Ann Surg, 2015,261(4):670-677. DOI: 10.1097/SLA.0000000000000862. doi:10.1097/SLA.0000000000000862pmid:25119122 |
[16] | Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma[J]. Eur J Cance, 2014,50(1):121-127. DOI: 10.1016/j.ejca.2013.09.007. |
[17] | Mignard C, Deschamps Huvier A, Gillibert A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma[J]. J Oncol, 2018,2018:1908065. DOI: 10.1155/2018/1908065. doi:10.1155/2018/1908065pmid:30631354 |
[18] | Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma[J]. Cancer, 2016,122(21):3354-3362. DOI: 10.1002/cncr.30259. doi:10.1002/cncr.30259pmid:27533633 |
[19] | Dodds TJ, Wilmott JS, Jackett LA, et al. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases[J]. Pathology, 2019,51(1):39-45. DOI: 10.1016/j.pathol.2018.09.060. doi:10.1016/j.pathol.2018.09.060pmid:30497801 |
[20] | Sakaizawa K, Ashida A, Uchiyama A, et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients[J]. J Dermatol Sci, 2015,80(1):33-37. DOI: 10.1016/j.jdermsci.2015.07.012. doi:10.1016/j.jdermsci.2015.07.012pmid:26282084 |
[21] | Gong HZ, Zheng HY, Li J. The clinical significance of KIT mutations in melanoma: a meta-analysis[J]. Melanoma Res, 2018,28(4):259-270. DOI: 10.1097/CMR.0000000000000454. doi:10.1097/CMR.0000000000000454pmid:29746316 |
[22] | Cinotti E, Chevallier J, Labeille B, et al. Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases[J]. J Eur Acad Dermatol Venereology, 2017,31(11):1834-1840. DOI: 10.1111/jdv.14353. |
[23] | Schaefer T, Satzger I, Gutzmer R. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: a retrospective analysis of 75 patients[J]. Medicine (Baltimore), 2017,96(1):e5753. DOI: 10.1097/MD.0000000000005753. doi:10.1097/MD.0000000000005753 |
[24] | Wei X, Mao L, Chi Z, et al. Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study[J]. Oncol Res, 2019,27(4):495-501. DOI: 10.3727/096504018X-15331163433914. doi:10.3727/096504018X15331163433914pmid:30075827 |
[25] | Buchbinder EI, Sosman JA, Lawrence DP, et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma[J]. Cancer, 2015,121(22):4007-4015. DOI: 10.1002/cncr.29622. doi:10.1002/cncr.29622pmid:26264378 |
[26] | Kalinsky K, Lee S, Rubin KM, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage Ⅳ mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)[J]. Cancer, 2017,123(14):2688-2697. DOI: 10.1002/cncr.30663. doi:10.1002/cncr.30663pmid:28334439 |
[27] | Alrwas A, Papadopoulos NE, Cain S, et al. Phase Ⅰ trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma[J]. Melanoma Res, 2014,24(4):342-348. DOI: 10.1097/CMR.0000000000000062. doi:10.1097/CMR.0000000000000062 |
[28] | Heppt MV, Roesch A, Weide B, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma[J]. Eur J Cancer, 2017,81:36-44. DOI: 10.1016/j.ejca.2017.05.014. doi:10.1016/j.ejca.2017.05.014pmid:28600969 |
[29] | Cui C, Lian B, Zhou L, et al. Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients[J]. Ann Surg Oncol, 2018,25(8):2184-2192. DOI: 10.1245/s10434-018-6503-9. doi:10.1245/s10434-018-6503-9pmid:29748886 |
[30] | Chae WY, Lee JL, Cho DH, et al. Preliminary suggestion about staging of anorectal malignant melanoma may be used to predict prognosis[J]. Cancer Res Treat, 2016,48(1):240-249. DOI: 10.4143/crt.2014.305. doi:10.4143/crt.2014.305pmid:25761474 |
[1] | 刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325. |
[2] | 钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效:一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331. |
[3] | 杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337. |
[4] | 袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343. |
[5] | 张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. |
[6] | 许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363. |
[7] | 王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. |
[8] | 张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375. |
[9] | 高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381. |
[10] | 王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285. |
[11] | 张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291. |
[12] | 陈琦, 徐晨阳, 王寅, 雷大鹏.高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302. |
[13] | 王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟.铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311. |
[14] | 王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203. |
[15] | 萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||